astrazeneca glp 1 GLP-1 pill shows promise in obesity, diabetes trials ADA: AZ's oral GLP-1 shows

doi: 10.2337/db13-0805

In this regard, it is noteworthy that a selective glucagon receptor antagonist increased hepatic fat in patients with T2D 23

However, no clinical evidence exists demonstrating better outcomes using potent, short-acting DPP-IV inhibitors instead of longer-acting DPP-IV inhibitors, nor has there been a large study on the efficacy of the cleavage products of GLP-1 (7-36) (and GLP-1 [9-37])

1 In Mr

Patients receiving semaglutide 2.4 mg in this trial lost 9.9% of their body weight, compared with 0.4% in those receiving placebo [33]

Microdosing in the GLP-1 context typically means starting below the labeled dose or extending titration intervals